Beam Therapeutics Inc
NASDAQ:BEAM

Watchlist Manager
Beam Therapeutics Inc Logo
Beam Therapeutics Inc
NASDAQ:BEAM
Watchlist
Price: 25.05 USD 6.23% Market Closed
Market Cap: 2.1B USD
Have any thoughts about
Beam Therapeutics Inc?
Write Note

Intrinsic Value

BEAM's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one BEAM stock under the Base Case scenario is 9.64 USD. Compared to the current market price of 25.05 USD, Beam Therapeutics Inc is Overvalued by 62%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BEAM Intrinsic Value
9.64 USD
Overvaluation 62%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Beam Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BEAM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BEAM?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Beam Therapeutics Inc

Provide an overview of the primary business activities
of Beam Therapeutics Inc.

What unique competitive advantages
does Beam Therapeutics Inc hold over its rivals?

What risks and challenges
does Beam Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Beam Therapeutics Inc recently?

Summarize the latest earnings call
of Beam Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Beam Therapeutics Inc.

Provide P/S
for Beam Therapeutics Inc.

Provide P/E
for Beam Therapeutics Inc.

Provide P/OCF
for Beam Therapeutics Inc.

Provide P/FCFE
for Beam Therapeutics Inc.

Provide P/B
for Beam Therapeutics Inc.

Provide EV/S
for Beam Therapeutics Inc.

Provide EV/GP
for Beam Therapeutics Inc.

Provide EV/EBITDA
for Beam Therapeutics Inc.

Provide EV/EBIT
for Beam Therapeutics Inc.

Provide EV/OCF
for Beam Therapeutics Inc.

Provide EV/FCFF
for Beam Therapeutics Inc.

Provide EV/IC
for Beam Therapeutics Inc.

Show me price targets
for Beam Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Beam Therapeutics Inc?

How accurate were the past Revenue estimates
for Beam Therapeutics Inc?

What are the Net Income projections
for Beam Therapeutics Inc?

How accurate were the past Net Income estimates
for Beam Therapeutics Inc?

What are the EPS projections
for Beam Therapeutics Inc?

How accurate were the past EPS estimates
for Beam Therapeutics Inc?

What are the EBIT projections
for Beam Therapeutics Inc?

How accurate were the past EBIT estimates
for Beam Therapeutics Inc?

Compare the revenue forecasts
for Beam Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Beam Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Beam Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Beam Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Beam Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Beam Therapeutics Inc with its peers.

Analyze the financial leverage
of Beam Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Beam Therapeutics Inc.

Provide ROE
for Beam Therapeutics Inc.

Provide ROA
for Beam Therapeutics Inc.

Provide ROIC
for Beam Therapeutics Inc.

Provide ROCE
for Beam Therapeutics Inc.

Provide Gross Margin
for Beam Therapeutics Inc.

Provide Operating Margin
for Beam Therapeutics Inc.

Provide Net Margin
for Beam Therapeutics Inc.

Provide FCF Margin
for Beam Therapeutics Inc.

Show all solvency ratios
for Beam Therapeutics Inc.

Provide D/E Ratio
for Beam Therapeutics Inc.

Provide D/A Ratio
for Beam Therapeutics Inc.

Provide Interest Coverage Ratio
for Beam Therapeutics Inc.

Provide Altman Z-Score Ratio
for Beam Therapeutics Inc.

Provide Quick Ratio
for Beam Therapeutics Inc.

Provide Current Ratio
for Beam Therapeutics Inc.

Provide Cash Ratio
for Beam Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Beam Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Beam Therapeutics Inc?

What is the current Free Cash Flow
of Beam Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Beam Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Beam Therapeutics Inc

Current Assets 945.5m
Cash & Short-Term Investments 925.8m
Other Current Assets 19.8m
Non-Current Assets 225.8m
PP&E 218.2m
Other Non-Current Assets 7.6m
Current Liabilities 166.2m
Accounts Payable 3.8m
Accrued Liabilities 64.7m
Other Current Liabilities 97.7m
Non-Current Liabilities 213.8m
Other Non-Current Liabilities 213.8m
Efficiency

Earnings Waterfall
Beam Therapeutics Inc

Revenue
349.6m USD
Operating Expenses
-532.3m USD
Operating Income
-182.7m USD
Other Expenses
39.1m USD
Net Income
-143.6m USD

Free Cash Flow Analysis
Beam Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BEAM Profitability Score
Profitability Due Diligence

Beam Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
27/100
Profitability
Score

Beam Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

BEAM Solvency Score
Solvency Due Diligence

Beam Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
51/100
Solvency
Score

Beam Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BEAM Price Targets Summary
Beam Therapeutics Inc

Wall Street analysts forecast BEAM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BEAM is 50.27 USD with a low forecast of 23.23 USD and a high forecast of 84 USD.

Lowest
Price Target
23.23 USD
7% Downside
Average
Price Target
50.27 USD
101% Upside
Highest
Price Target
84 USD
235% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BEAM?

Click here to dive deeper.

Dividends

Beam Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for BEAM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BEAM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

BEAM News

Profile

Beam Therapeutics Inc Logo
Beam Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.1B USD

Dividend Yield

0%

Description

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. The company is headquartered in Cambridge, Massachusetts and currently employs 341 full-time employees. The company went IPO on 2020-02-06. The firm is focused on developing precision genetic medicines based on its base editing technology to provide life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company’s base editing technology of therapeutic applications pursue a suite of both clinically validated and delivery modalities, depending on tissue type, which includes electroporation for delivery to blood cells and immune cells ex vivo; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future, and adeno-associated viral vectors (AAV), for in vivo viral delivery to the eye and potentially other organs. The firm has four development candidates, which include BEAM-101, BEAM-102, BEAM-201 and BEAM-301.

Contact

MASSACHUSETTS
Cambridge
26 Landsdowne St
+18573278775.0
beamtx.com

IPO

2020-02-06

Employees

341

Officers

CEO & Director
Mr. John M. Evans M.B.A.
President
Dr. Giuseppe Ciaramella Ph.D.
Senior VP, Chief Legal Officer & Corporate Secretary
Dr. Christine P. Bellon J.D., Ph.D.
Chief Medical Officer
Dr. Amy Simon M.D.
Co-Founder
Dr. J. Keith Joung M.D., Ph.D.
Senior VP of Finance & Treasurer
Bethany J. Cavanagh
Show More
Chief Technology Officer
Dr. Manmohan Singh Ph.D.
Chief Scientific Officer
Dr. Gopi Shanker Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one BEAM stock?

The intrinsic value of one BEAM stock under the Base Case scenario is 9.64 USD.

Is BEAM stock undervalued or overvalued?

Compared to the current market price of 25.05 USD, Beam Therapeutics Inc is Overvalued by 62%.

Back to Top